Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public

BioPharma Dive (WEB 01/16/2020)

SAN FRANCISCO — Novartis sparked a new round of drug pricing criticism last May when the Swiss pharma revealed its new gene therapy Zolgensma would cost $2.1 million per patient.

Pipeline products to prioritize: "Those programs existed as part of the acquisition of AveXis. Since then, we started partnering with [the Novartis Institutes of Biomedical Research] to apply this platform to different diseases. The first one we announced is a project for Friedreich's ataxia, a muscle-wasting disease."

Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public